Literature DB >> 23933792

[Optic nerve neuritis].

H Steffen1.   

Abstract

Optic nerve neuritis is one of the most important differential diagnoses of visual loss in young and middle aged adults. The prognosis in terms of functional outcome is generally good. The diagnosis of optic neuritis is clinical. Steroids can reduce the recovery time but do not affect the long-term functional outcome. Magnetic resonance imaging (MRI) is the most important investigation for assessing an associated risk of multiple sclerosis. Optical coherence tomography (OCT) contributes additional details on the course and functional outcome of optic neuritis. In the future OCT may additionally contribute to the relationship between optic neuritis and possible associated multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23933792     DOI: 10.1007/s00347-013-2906-y

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  17 in total

1.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Authors:  L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

2.  The optic neuritis treatment trial: a definitive answer and profound impact with unexpected results.

Authors:  Nicholas J Volpe
Journal:  Arch Ophthalmol       Date:  2008-07

3.  Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis.

Authors:  R T Naismith; N T Tutlam; J Xu; J B Shepherd; E C Klawiter; S-K Song; A H Cross
Journal:  Neurology       Date:  2009-07-07       Impact factor: 9.910

4.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Authors:  G Comi; M Filippi; F Barkhof; L Durelli; G Edan; O Fernández; H Hartung; P Seeldrayers; P S Sørensen; M Rovaris; V Martinelli; O R Hommes
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

5.  High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial.

Authors:  Roy W Beck; Jonathan D Trobe; Pamela S Moke; Robin L Gal; Dongyuan Xing; M Tariq Bhatti; Michael C Brodsky; Edward G Buckley; Georgia A Chrousos; James Corbett; Eric Eggenberger; James A Goodwin; Barrett Katz; David I Kaufman; John L Keltner; Mark J Kupersmith; Neil R Miller; Sarkis Nazarian; Silvia Orengo-Nania; Peter J Savino; William T Shults; Craig H Smith; Michael Wall
Journal:  Arch Ophthalmol       Date:  2003-07

6.  Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies.

Authors:  J N Ratchford; M E Quigg; A Conger; T Frohman; E Frohman; L J Balcer; P A Calabresi; D A Kerr
Journal:  Neurology       Date:  2009-07-28       Impact factor: 9.910

7.  Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

Authors:  G Comi; V Martinelli; M Rodegher; L Moiola; O Bajenaru; A Carra; I Elovaara; F Fazekas; H P Hartung; J Hillert; J King; S Komoly; C Lubetzki; X Montalban; K M Myhr; M Ravnborg; P Rieckmann; D Wynn; C Young; M Filippi
Journal:  Lancet       Date:  2009-10-06       Impact factor: 79.321

Review 8.  The spectrum of neuromyelitis optica.

Authors:  Dean M Wingerchuk; Vanda A Lennon; Claudia F Lucchinetti; Sean J Pittock; Brian G Weinshenker
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

9.  Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

Authors:  Ludwig Kappos; Mark S Freedman; Chris H Polman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederik Barkhof; Ernst-Wilhelm Radü; Carola Metzig; Lars Bauer; Vivian Lanius; Rupert Sandbrink; Christoph Pohl
Journal:  Lancet Neurol       Date:  2009-09-10       Impact factor: 44.182

10.  Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin.

Authors:  A Tselis; J Perumal; C Caon; S Hreha; W Ching; M Din; G Van Stavern; O Khan
Journal:  Eur J Neurol       Date:  2008-08-21       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.